Use of HMG-CoA Reductase Inhibitors after Kidney and Heart Transplantation

No abstract is available for this paper.

• Publication year

  1997

• Venue

  BioDrugs

• Publication date

  1997-11-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.2165/00063030-199708050-00006PMID 18020528
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Lovastatin

  2012cited by this paper
• Cardiovascular disease after renal transplantation.

  2000cited by this paper
• The pilot study.

  2000cited by this paper
• PREVENTION OF CORONARY HEART DISEASE WITH PRAVASTATIN IN MEN WITH HYPERCHOLESTEROLEMIA

  2000cited by this paper
• The effect of pravastatin on acute rejection after kidney transplantation--a pilot study.

  1996cited by this paper
• Comparison of pravastatin and lovastatin in renal transplant patients receiving cyclosporine.

  1996cited by this paper
• Myoglobinuric renal failure due to long-standing lovastatin therapy in a patient with pre-existing chronic renal insufficiency.

  1996cited by this paper
• Clinical utility of antilipidemic therapies in chronic renal allograft failure.

  1995cited by this paper
• Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group.

  1995cited by this paper
• Effect of fluvastatin for safely lowering atherogenic lipids in renal transplant patients receiving cyclosporine.

  1995cited by this paper
• Lipid-lowering therapy in patients with renal disease.

  1995cited by this paper
• Hypertension and ischaemic heart disease in renal transplant recipients.

  1995cited by this paper
• Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia

  1995cited by this paper
• Effect of pravastatin on outcomes after cardiac transplantation.

  1995cited by this paper
• Abnormal lipoprotein (a) and lipid profiles in renal allograft recipients: effects of treatment with pravastatin.

  1995cited by this paper
• Hyperlipidaemia in renal transplantation—risk factor for long‐term graft outcome

  1995cited by this paper
• The efficacy and safety of fluvastatin in hypercholesterolemia in renal transplant recipients.

  1995cited by this paper
• A preliminary report of the safety and efficacy of fluvastatin for hypercholesterolemia in renal transplant patients receiving cyclosporine.

  1995cited by this paper
• Clinical Pharmacokinetics of Pravastatin

  1994cited by this paper
• Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S)

  1994cited by this paper
• Scandinavian simvastatin study (4S)

  1994cited by this paper
• Prevention of coronary heart disease in clinical practice. Recommendations of the Task Force of the European Society of Cardiology, European Atherosclerosis Society and European Society of Hypertension.

  1994cited by this paper
• Low-dose simvastatin is a well-tolerated and efficacious cholesterol-lowering agent in ciclosporin-treated kidney transplant recipients: double-blind, randomized, placebo-controlled study in 40 patients.

  1994cited by this paper
• Prevention of coronary heart disease in clinical practice

  1994cited by this paper
• Serum lipoprotein (a) in renal transplant recipients receiving cyclosporin monotherapy.

  1993cited by this paper
• The influence of pretransplant lipoprotein abnormalities on the early results of renal transplantation

  1993cited by this paper
• Low-dose simvastatin is safe in hyperlipidaemic renal transplant patients.

  1993cited by this paper
• Plasma concentration profiles of simvastatin 3-hydroxy-3-methyl-glutaryl-coenzyme A reductase inhibitory activity in kidney transplant recipients with and without ciclosporin.

  1993cited by this paper
• Viewpoint on the Report of the National Cholesterol Education Program Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults.

  1993cited by this paper
• Role of lipid disturbances in the atherosclerosis of renal transplant patients

  1992cited by this paper
• Pharmacokinetics of Fluvastatin After Single and Multiple Doses in Normal Volunteers

  1992cited by this paper
• THE EFFECTS OF PRAVASTATIN ON HYPERLIPIDEMIA IN RENAL TRANSPLANT RECIPIENTS1

  1992cited by this paper
• Decreased postheparin lipolytic activity in renal transplant recipients with cyclosporin A.

  1991cited by this paper
• Chemotaxis of the monocyte cell line U937: dependence on cholesterol and early mevalonate pathway products.

  1991cited by this paper
• Low-dose simvastatin for the treatment of hypercholesterolaemia in recipients of cardiac transplantation.

  1991cited by this paper
• Independent effects of cyclosporine and prednisone on posttransplant hypercholesterolemia.

  1991cited by this paper
• Lipoprotein-apolipoprotein changes in renal transplant recipients: a 2-year follow-up.

  1991cited by this paper
• The adverse impact of cyclosporine on serum lipids in renal transplant recipients.

  1991cited by this paper
• Biotransformation of lovastatin. IV. Identification of cytochrome P450 3A proteins as the major enzymes responsible for the oxidative metabolism of lovastatin in rat and human liver microsomes.

  1991cited by this paper
• Hypercholesterolemia in long-term survivors of heart transplantation: an early marker of accelerated coronary artery disease.

  1991cited by this paper
• Biotransformation of lovastatin. I. Structure elucidation of in vitro and in vivo metabolites in the rat and mouse.

  1990cited by this paper
• Low-dose lovastatin safely lowers cholesterol after cardiac transplantation.

  1990cited by this paper
• Disposition of pravastatin sodium, a tissue-selective HMG-CoA reductase inhibitor, in healthy subjects.

  1990cited by this paper
• Renal allograft rejection. Possible involvement of antibody-dependent cell-mediated cytotoxicity.

  1990cited by this paper
• Biotransformation of lovastatin--III. Effect of cimetidine and famotidine on in vitro metabolism of lovastatin by rat and human liver microsomes.

  1990cited by this paper
• Reversal of lovastatin‐mediated inhibition of natural killer cell cytotoxicity by interleukin 2

  1990cited by this paper
• Regulation of the mevalonate pathway

  1990cited by this paper
• Cyclosporin A drug interactions. Screening for inducers and inhibitors of cytochrome P-450 (cyclosporin A oxidase) in primary cultures of human hepatocytes and in liver microsomes.

  1990cited by this paper
• Effects of cyclosporine therapy on plasma lipoprotein levels.

  1989cited by this paper
• Suppression of lymphoid cell function in vitro by inhibition of 3-hydroxy-3-methylglutaryl coenzyme A reductase by lovastatin.

  1989cited by this paper
• The physiological disposition of lovastatin.

  1989cited by this paper
• LIPID ABNORMALITIES IN CYCLOSPORINE‐PREDNISONE‐TREATED RENAL TRANSPLANT RECIPIENTS

  1989cited by this paper
• Cyclosporine, low-density lipoprotein, and cholesterol.

  1988cited by this paper
• Cyclosporine, low-density lipoprotein, and cholesterol.

  1988cited by this paper
• Rhabdomyolysis in patients receiving lovastatin after cardiac transplantation.

  1988cited by this paper
• Persistent Hyperlipidemia in Renal Transplant Patients

  1987cited by this paper
• Alterations in lipid and carbohydrate metabolism attributable to cyclosporin A in renal transplant recipients.

  1986cited by this paper
• Alterations in lipid and carbohydrate metabolism attributable to cyclosporin A in renal transplant recipients.

  1986cited by this paper
• The role of propranolol therapy and proteinuria in the etiology of post renal transplantation hyperlipidemia.

  1982cited by this paper
• The role of propranolol therapy and proteinuria in the etiology of post renal transplantation hyperlipidemia.

  1982cited by this paper

• Post-Kidney Transplant Modification of Cardiovascular Risk

  2017cites this paper
• National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III)

  2015cites this paper
• Pathophysiologic and Treatment Strategies for Cardiovascular Disease in End-Stage Renal Disease and Kidney Transplantations

  2014cites this paper
• Are Statins Reliable Drugs as Mentioned? Indications and Risks for Statins

  2014cites this paper
• Dyslipidemia in Patients with Chronic and End-Stage Kidney Disease

  2013cites this paper
• Addressing cardiovascular risk beyond low-density lipoprotein cholesterol: the high-density lipoprotein cholesterol story

  2004cites this paper
• ACC/AHA/NHLBI clinical advisory on the use and safety of statins.

  2002cites this paper
• ACC/AHA/NHLBI Clinical Advisory on the Use and Safety of Statins.

  2002cites this paper
• Distribution of Cyclosporin in Organ Transplant Recipients

  2002cites this paper
• ACC/AHA/NHLBI Clinical Advisory on the Use and Safety of Statins.

  2002cites this paper
• Impact of dyslipidaemia in renal transplant recipients.

  2000cites this paper
• Clinically Significant Cytochrome P‐450 Drug Interactions—A Comment

  1998cites this paper